Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer

Takahiro Yoshida, Kideok Jin, Hong Song, Sunju Park, David L. Huso, Zhe Zhang, Han Liangfeng, Charles Zhu, Frank Bruchertseifer, Alfred Morgenstern, George Sgouros, Saraswati Sukumar

Research output: Contribution to journalArticle

Abstract

The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate 225Ac linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the alpha-emitter 225Ac (half-life, 10 days) delivers highly cytotoxic, focused doses of radiation to tumors. Systemic 225Ac, however, elicits hematologic toxicity and at high doses free 213Bi, generated by its decay, causes renal toxicity. I.duc delivery of the radioimmunoconjugate could bypass its systemic toxicity. Bioluminescent imaging showed that the therapeutic efficacy of intraductal 225Ac-trastuzumab (10-40 nCi per mammary gland; 30-120 nCi per mouse) in a DCIS model of human SUM225 cancer cells in NSG mice was significantly higher (p225Ac-trastuzumab deserves greater attention for future clinical development as a treatment modality for early breast cancer.

Original languageEnglish (US)
Pages (from-to)33306-33315
Number of pages10
JournalOncotarget
Volume7
Issue number22
DOIs
StatePublished - May 31 2016

Fingerprint

Alpha Particles
Carcinoma, Intraductal, Noninfiltrating
Radioisotopes
Immunoconjugates
Breast Neoplasms
Radiation
Human Mammary Glands
Half-Life
Neoplasms
Breast
Kidney
Trastuzumab
Therapeutics

Keywords

  • Breast cancer
  • Ductal carcinoma in situ
  • Intraductal
  • Radioimmunotherapy
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology

Cite this

Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. / Yoshida, Takahiro; Jin, Kideok; Song, Hong; Park, Sunju; Huso, David L.; Zhang, Zhe; Liangfeng, Han; Zhu, Charles; Bruchertseifer, Frank; Morgenstern, Alfred; Sgouros, George; Sukumar, Saraswati.

In: Oncotarget, Vol. 7, No. 22, 31.05.2016, p. 33306-33315.

Research output: Contribution to journalArticle

Yoshida, T, Jin, K, Song, H, Park, S, Huso, DL, Zhang, Z, Liangfeng, H, Zhu, C, Bruchertseifer, F, Morgenstern, A, Sgouros, G & Sukumar, S 2016, 'Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer', Oncotarget, vol. 7, no. 22, pp. 33306-33315. https://doi.org/10.18632/oncotarget.8949
Yoshida, Takahiro ; Jin, Kideok ; Song, Hong ; Park, Sunju ; Huso, David L. ; Zhang, Zhe ; Liangfeng, Han ; Zhu, Charles ; Bruchertseifer, Frank ; Morgenstern, Alfred ; Sgouros, George ; Sukumar, Saraswati. / Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. In: Oncotarget. 2016 ; Vol. 7, No. 22. pp. 33306-33315.
@article{031d4ba8c1f14cb9a05c19adb2ae6f22,
title = "Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer",
abstract = "The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate 225Ac linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the alpha-emitter 225Ac (half-life, 10 days) delivers highly cytotoxic, focused doses of radiation to tumors. Systemic 225Ac, however, elicits hematologic toxicity and at high doses free 213Bi, generated by its decay, causes renal toxicity. I.duc delivery of the radioimmunoconjugate could bypass its systemic toxicity. Bioluminescent imaging showed that the therapeutic efficacy of intraductal 225Ac-trastuzumab (10-40 nCi per mammary gland; 30-120 nCi per mouse) in a DCIS model of human SUM225 cancer cells in NSG mice was significantly higher (p225Ac-trastuzumab deserves greater attention for future clinical development as a treatment modality for early breast cancer.",
keywords = "Breast cancer, Ductal carcinoma in situ, Intraductal, Radioimmunotherapy, Trastuzumab",
author = "Takahiro Yoshida and Kideok Jin and Hong Song and Sunju Park and Huso, {David L.} and Zhe Zhang and Han Liangfeng and Charles Zhu and Frank Bruchertseifer and Alfred Morgenstern and George Sgouros and Saraswati Sukumar",
year = "2016",
month = "5",
day = "31",
doi = "10.18632/oncotarget.8949",
language = "English (US)",
volume = "7",
pages = "33306--33315",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "22",

}

TY - JOUR

T1 - Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer

AU - Yoshida, Takahiro

AU - Jin, Kideok

AU - Song, Hong

AU - Park, Sunju

AU - Huso, David L.

AU - Zhang, Zhe

AU - Liangfeng, Han

AU - Zhu, Charles

AU - Bruchertseifer, Frank

AU - Morgenstern, Alfred

AU - Sgouros, George

AU - Sukumar, Saraswati

PY - 2016/5/31

Y1 - 2016/5/31

N2 - The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate 225Ac linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the alpha-emitter 225Ac (half-life, 10 days) delivers highly cytotoxic, focused doses of radiation to tumors. Systemic 225Ac, however, elicits hematologic toxicity and at high doses free 213Bi, generated by its decay, causes renal toxicity. I.duc delivery of the radioimmunoconjugate could bypass its systemic toxicity. Bioluminescent imaging showed that the therapeutic efficacy of intraductal 225Ac-trastuzumab (10-40 nCi per mammary gland; 30-120 nCi per mouse) in a DCIS model of human SUM225 cancer cells in NSG mice was significantly higher (p225Ac-trastuzumab deserves greater attention for future clinical development as a treatment modality for early breast cancer.

AB - The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate 225Ac linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu, while the alpha-emitter 225Ac (half-life, 10 days) delivers highly cytotoxic, focused doses of radiation to tumors. Systemic 225Ac, however, elicits hematologic toxicity and at high doses free 213Bi, generated by its decay, causes renal toxicity. I.duc delivery of the radioimmunoconjugate could bypass its systemic toxicity. Bioluminescent imaging showed that the therapeutic efficacy of intraductal 225Ac-trastuzumab (10-40 nCi per mammary gland; 30-120 nCi per mouse) in a DCIS model of human SUM225 cancer cells in NSG mice was significantly higher (p225Ac-trastuzumab deserves greater attention for future clinical development as a treatment modality for early breast cancer.

KW - Breast cancer

KW - Ductal carcinoma in situ

KW - Intraductal

KW - Radioimmunotherapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84973539295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973539295&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8949

DO - 10.18632/oncotarget.8949

M3 - Article

VL - 7

SP - 33306

EP - 33315

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -